pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›EYLEA HD
drug · protein
save

EYLEA HD

Marketedupdated 3mo ago
by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Approved
annual revenue · 2024–2024peak $9.4B
2024: $9.4B2024$9.4B
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval44 co-mentions · 15 sources
  • drugEylea32 co-mentions · 15 sources
  • drugYESAFILI18 co-mentions · 7 sources
  • drugaflibercept biosimilar17 co-mentions · 10 sources
  • drugOPUVIZ8 co-mentions · 4 sources
  • drugENZEEVU6 co-mentions · 3 sources
  • companySamsung Bioepis Co Ltd4 co-mentions · 4 sources
  • companyBiocon Biologics Ltd4 co-mentions · 2 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 16 approved and 39 investigational indications.

indications

investigational
Diabetic Macular Edema

targets

Placenta growth factorVascular endothelial growth factor A, long form

all catalysts(5)

approval · 5
Aug 18, 2023
approval
$REGN797.00-1.37%
3y ago
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Dec 14, 2023
approval
$REGN797.00-1.37%
3y ago
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Oct 10, 2024
approval
$REGN797.00-1.37%
2y ago
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Nov 19, 2025
approval
$REGN797.00-1.37%
9mo ago
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Apr 2, 2026
approval
$REGN797.00-1.37%
4mo ago
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→

Trials studying EYLEA HD

  • phase3Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)recruitingn=388
  • phase3A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56active not recruitingn=400
  • phase3CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMErecruitingn=240
  • phase3COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMErecruitingn=240
  • phase2A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathyactive not recruitingn=190
  • phase3A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degenerationrecruitingn=304
  • phase3A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)not yet recruitingn=1,104
  • phase3A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)recruitingn=960
more trials →

News(9)

  • Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
    Despite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.
    biospace · 21h ago
  • Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
    Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of…
    fiercebiotech · 2d ago
  • Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
    Calls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.
    biospace · 12d ago
  • FDA scientists question Capricor data; Legend CEO steps down
    Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
    biopharma_dive · 15d ago
  • Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
    Roche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…
    fiercebiotech · 20d ago
  • ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
    The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
    biopharma_dive · 1mo ago
  • Regeneron immunotherapy combo comes up short in melanoma trial
    A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…
    biopharma_dive · 2mo ago
  • Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
    Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
    biopharma_dive · 3mo ago
  • Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
    Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
    biopharma_dive · 3mo ago
brand
EYLEA HD
trade names
Eylea, Yesafili, Zaltrap
generic
AFLIBERCEPT
MOA
12.1 Mechanism of Action Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, and thereby can inhibit the binding and activation of these cognate VEGF receptors.
indication
wet AMD, diabetic macular edema, retinal vein occlusion
phase
marketed
approved
2011-11-18
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?